In summary, these data support the notion that new multitarget drugs acting simultaneously on different neuropeptide receptors (and possibly upon other important targets such as monoaminergic receptors) could have relevant therapeutic potential for the treatment of complex CNS pathologies such as anxiety, depression or drug addiction. Here, NPSR1 is linked to depressive symptom measurement.